TY - GEN
T1 - P188: One year survival of treated non-small cell lung carcinoma in elderly in Cipto Mangunkusumo Hospital and Dharmais Cancer Hospital
AU - Praptini, M.n.
AU - Sari, N.k.
AU - Soetandyo, N.
AU - Rumende, C.m.
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Background: Non-small cell lung carcinoma survival in elderlyhas been studied before but not many studies have consideredfactors such as stage, functional status, comorbidities and bodymass index.Aim: To evaluate differences of treated non-small cell lung carcinoma one year survival between non-elderly and elderly considering stages, functional status, body mass index and comorbidities.Methods: Retrospective cohort design and survival analysis wereused to 227 patients with non-small cell lung cancer that beingtreated at Cipto Mangunkusumo Hospital and Dharmais CancerHospital between 2002 and 2012 that divided into 2 groupsaccording to age at diagnosis (<60 years and >60 years).Results and Discussion: Median age was 58.4 years (29–91 years)and both age groups percentage were almost similar (<60 years53.7% and ≥60 years 46.3%). Male sex was 74.0%. Median bodymass index was 22.06% (12.9–35.6) kg/m2 (normoweight 60.9%).The most common histologic type was adenocarcinoma (37.9%),stage III and IV (39.9% and 45.7%, respectively), chemotherapy68.3% followed by radiotherapy 42.7% and operation 4.4%. Themost common chemotherapy was combination of platinum groupand paclitaxel or docetaxel (33.8%). One year mortality 68.0% and61.9% for <60 and >60 years of age, survival median 8 and 9 months,crude HR 0.859 (0.620–1.188). Bivariate analysis found no significantrelation between age and one year survival.Conclusion: Age didn’t influence one year survival of treatednon-small cell lung carcinoma at Cipto Mangunkusumo Hospitaland Dharmais Cancer Hospital considering stage, functional status,comorbidities and body mass index.Keywords: Elderly, Lung Cancer, Survival
AB - Background: Non-small cell lung carcinoma survival in elderlyhas been studied before but not many studies have consideredfactors such as stage, functional status, comorbidities and bodymass index.Aim: To evaluate differences of treated non-small cell lung carcinoma one year survival between non-elderly and elderly considering stages, functional status, body mass index and comorbidities.Methods: Retrospective cohort design and survival analysis wereused to 227 patients with non-small cell lung cancer that beingtreated at Cipto Mangunkusumo Hospital and Dharmais CancerHospital between 2002 and 2012 that divided into 2 groupsaccording to age at diagnosis (<60 years and >60 years).Results and Discussion: Median age was 58.4 years (29–91 years)and both age groups percentage were almost similar (<60 years53.7% and ≥60 years 46.3%). Male sex was 74.0%. Median bodymass index was 22.06% (12.9–35.6) kg/m2 (normoweight 60.9%).The most common histologic type was adenocarcinoma (37.9%),stage III and IV (39.9% and 45.7%, respectively), chemotherapy68.3% followed by radiotherapy 42.7% and operation 4.4%. Themost common chemotherapy was combination of platinum groupand paclitaxel or docetaxel (33.8%). One year mortality 68.0% and61.9% for <60 and >60 years of age, survival median 8 and 9 months,crude HR 0.859 (0.620–1.188). Bivariate analysis found no significantrelation between age and one year survival.Conclusion: Age didn’t influence one year survival of treatednon-small cell lung carcinoma at Cipto Mangunkusumo Hospitaland Dharmais Cancer Hospital considering stage, functional status,comorbidities and body mass index.Keywords: Elderly, Lung Cancer, Survival
UR - https://linkinghub.elsevier.com/retrieve/pii/S1878764914703638
U2 - 10.1016/S1878-7649(14)70363-8
DO - 10.1016/S1878-7649(14)70363-8
M3 - Conference contribution
VL - 5
SP - S143
BT - European Geriatric Medicine
ER -
